{"gene":"BCLAF1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1999,"finding":"BCLAF1 (Btf) was identified as a novel protein that interacts with anti-apoptotic proteins E1B 19K, Bcl-2, and Bcl-xL but not with pro-apoptotic Bax. Btf binds DNA in vitro and represses transcription in reporter assays. E1B 19K, Bcl-2, and Bcl-xL sequester Btf in the cytoplasm and block its transcriptional repression activity. Sustained overexpression of Btf in HeLa cells induced apoptosis, which was inhibited by E1B 19K.","method":"Yeast two-hybrid screen, DNA binding assay in vitro, transcriptional reporter assay, subcellular localization, overexpression/apoptosis assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (yeast two-hybrid, in vitro DNA binding, reporter assay, cell-based apoptosis), foundational paper replicated in subsequent studies","pmids":["10330179"],"is_preprint":false},{"year":2004,"finding":"Emerin binds BCLAF1 (Btf) with an equilibrium affinity (KD) of ~100 nM; this interaction was mapped to two regions of emerin flanking its lamin-binding domain. Disease-causing emerin mutation S54F selectively disrupts emerin binding to Btf without affecting binding to BAF, lamin A, or GCL. In non-apoptotic HeLa cells, endogenous Btf localizes to dot-like structures in the nuclear interior; upon Fas-induced apoptosis, Btf redistributes to a zone near the nuclear envelope, indicating apoptosis-regulated subcellular localization.","method":"Yeast two-hybrid, biochemical binding assay (equilibrium affinity), clustered alanine-substitution mutagenesis, indirect immunofluorescence","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — equilibrium binding assay with mutagenesis plus direct localization by immunofluorescence, multiple orthogonal approaches in one study","pmids":["15009215"],"is_preprint":false},{"year":2007,"finding":"PKCδ transactivates TP53 expression by interacting with BCLAF1 (Btf) and co-occupying the TP53 core promoter element (CPE-TP53). Inhibition of PKCδ activity decreases Btf affinity for CPE-TP53, reducing TP53 mRNA and protein levels. RNAi-mediated disruption of Btf-mediated TP53 transcription suppresses TP53-dependent apoptosis following genotoxic stress.","method":"Reporter assay (promoter activity), co-immunoprecipitation, ChIP (co-occupancy of CPE-TP53), RNAi knockdown with apoptosis readout","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ChIP, and reporter assay with RNAi functional validation in one study","pmids":["17938203"],"is_preprint":false},{"year":2008,"finding":"Bclaf1 knockout mice demonstrate that Bclaf1 is required for proper spatial and temporal organization of smooth muscle lineage during the saccular stage of lung development and is essential for peripheral T-cell homeostasis. Bclaf1-deficient cells showed no defect in apoptosis in response to various apoptotic stimuli, contradicting its postulated role as a proapoptotic protein in vivo.","method":"Targeted gene knockout in mice, histological and cellular analysis of lung development and T-cell compartment","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout mouse with defined developmental and immune phenotypes, multiple tissue/cell-type readouts","pmids":["19008920"],"is_preprint":false},{"year":2011,"finding":"Sirt1 suppresses Bclaf1 transcription by deacetylating histone H3K56 at the bclaf1 promoter, counteracting p300-mediated H3K56 acetylation. Sirt1 is recruited to the bclaf1 promoter upon TCR/CD28 stimulation through a complex with p300 and NF-κB subunit Rel-A; blocking Rel-A nuclear translocation inhibits Sirt1 binding. Knockdown of Bclaf1 suppresses hyperactivation of Sirt1-null T cells.","method":"ChIP assay, siRNA knockdown, co-immunoprecipitation, histone acetylation analysis, T cell activation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, Co-IP, and functional knockdown with multiple orthogonal methods in one study","pmids":["21454709"],"is_preprint":false},{"year":2012,"finding":"BCLAF1 shows enhanced association with γH2AX specifically under high-dose ionizing radiation. BCLAF1 promotes apoptosis of irreparably damaged cells by disrupting p21-mediated inhibition of Caspase/cyclin E-dependent mitochondrial pathways. BCLAF1 co-localizes with γH2AX foci and stabilizes the Ku70/DNA-PKcs complex, facilitating NHEJ-based DSB repair in surviving cells. In tumor cells, BCLAF1 is intrinsically suppressed, leading to formation of anti-apoptotic Ku70-Bax complexes and disrupted Ku70/DNA-PKcs complexes.","method":"Co-immunoprecipitation, immunofluorescence co-localization, NHEJ repair assay, apoptosis assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and co-localization with functional readouts, single lab","pmids":["22833098"],"is_preprint":false},{"year":2012,"finding":"BCLAF1 functions as a restriction factor against human cytomegalovirus (HCMV). Immediately after infection, viral pp71 and UL35 proteins (delivered via virions) direct proteasomal degradation of BCLAF1. At late infection stages, virus-encoded miR-UL112-1 down-regulates BCLAF1. In the absence of BCLAF1 neutralization, viral gene expression and replication are inhibited.","method":"Protein degradation assay, viral miRNA functional assay, viral gene expression/replication assay with BCLAF1 knockdown/rescue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — two mechanistically distinct viral neutralization pathways experimentally identified with functional consequences on viral replication","pmids":["22645331"],"is_preprint":false},{"year":2013,"finding":"BCLAF1 (Btf) localizes at active transcription loci in a RNA Pol II-dependent manner and shows overlap with the exon junction complex protein Magoh. Btf depletion causes increased β-tropomyosin reporter transcripts and global increase of endogenous polyadenylated RNA in the cytoplasm, indicating a role for Btf in restricting mRNA nuclear export; TRAP150 depletion did not produce this effect.","method":"Fluorescence microscopy (localization at reporter gene loci), siRNA knockdown, nuclear/cytoplasmic fractionation with RT-PCR","journal":"Nucleus (Austin, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence (mRNA distribution) using knockdown and fractionation, single lab","pmids":["23778535"],"is_preprint":false},{"year":2014,"finding":"The splicing factor SRSF10 stimulates inclusion of BCLAF1 alternative exon5a, producing a specific BCLAF1 protein isoform. Knockdown of this exon5a-containing isoform inhibited growth of colorectal cancer cells, while its overexpression increased tumorigenic potential.","method":"Splicing assay, siRNA knockdown, overexpression, cell growth and tumorigenicity assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic splicing regulation identified with functional consequences, multiple cell-based methods, published in high-impact journal","pmids":["25091051"],"is_preprint":false},{"year":2016,"finding":"BCLAF1 is upregulated through the ATM/Nemo/NF-κB pathway during doxorubicin-induced senescence (TIS) and is a direct transcriptional target of p65 and c-Rel. BCLAF1 induction by NF-κB is required for C/EBPβ upregulation and IL-6/IL-8 transcription during TIS. BCLAF1 interacts with the leucine zipper region of C/EBPβ to cooperate in upregulating IL-8. BCLAF1 is required for effectiveness of doxorubicin-induced tumor suppression in a xenograft model.","method":"ChIP, co-immunoprecipitation, siRNA knockdown, reporter assay, xenograft tumor model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, Co-IP, and functional knockdown with multiple orthogonal methods in one study","pmids":["26794446"],"is_preprint":false},{"year":2017,"finding":"BCLAF1 and THRAP3 promote the DNA damage response by selective mRNA splicing and nuclear export of DDR transcripts, including ATM kinase mRNA. Loss of THRAP3 and/or BCLAF1 leads to sensitivity to DNA damaging agents, defective DNA repair, and genomic instability. Cancer-associated mutations in THRAP3 result in deregulated processing of THRAP3/BCLAF1-regulated transcripts and defective DNA repair.","method":"siRNA knockdown, DNA damage sensitivity assays, DNA repair assays, genomic instability assays, mRNA splicing/export analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with multiple orthogonal readouts (DNA repair, splicing, export), independently supported by clinical mutation data","pmids":["29112714"],"is_preprint":false},{"year":2017,"finding":"Depletion of BCLAF1 (Btf) and/or TRAP150 causes mitotic chromosome misalignment defects and altered abundance of transcripts encoding mitotic regulators, suggesting that Btf controls transcript abundance of mitotic checkpoint regulators, thereby affecting mitotic progression.","method":"siRNA knockdown, immunofluorescence (mitotic defects), RT-PCR (transcript levels)","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — knockdown with cellular phenotype and mRNA-level evidence, indirect mechanistic link, single lab","pmids":["28895891"],"is_preprint":false},{"year":2018,"finding":"BCLAF1 promotes HIF1A transcription via its bZIP domain in hepatocellular carcinoma cells, leading to increased transcription of VEGFA, TGFB, and EPO, which promote HCC-associated angiogenesis. HIF-1α levels and microvessel density decrease after shRNA-mediated BCLAF1 knockdown in xenograft tumors. A positive feedback loop exists: HIF-1α induces BCLAF1, which in turn stabilizes HIF-1α expression.","method":"shRNA knockdown, reporter assay, domain deletion (bZIP), xenograft tumor model, qRT-PCR, Western blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-based mechanistic evidence with in vivo xenograft validation, single lab","pmids":["30367150"],"is_preprint":false},{"year":2018,"finding":"Cry2 (but not Cry1) specifically interacts with BCLAF1 to stabilize mRNAs encoding cyclin D1 and Tmem176b, regulating circadian patterns of myoblast proliferation and myotube formation. BCLAF1 knockdown recapitulates Cry2 knockdown phenotypes: premature cell cycle exit and inefficient myogenic cell fusion.","method":"Co-immunoprecipitation, mRNA stability assay, siRNA knockdown, Cry2 knockout mice, myogenic differentiation assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP establishing Cry2-BCLAF1 interaction, mRNA stability assay, genetic KO and KD with parallel phenotypes across multiple methods","pmids":["29466738"],"is_preprint":false},{"year":2019,"finding":"BCLAF1 is degraded during alphaherpesvirus PRV and HSV-1 infection through the viral protein US3. BCLAF1 functions in type I interferon signaling by maintaining efficient STAT1 and STAT2 phosphorylation in response to IFNα and by directly interacting with ISRE sequences and STAT2 to facilitate ISGF3 binding for gene transcription. Knockdown or knockout of BCLAF1 significantly impairs IFNα-mediated gene transcription and antiviral activity.","method":"Protein degradation assay, Co-immunoprecipitation, ChIP/DNA binding assay, siRNA/CRISPR knockout, antiviral functional assays, STAT phosphorylation assay","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (IP, DNA binding, knockout, signaling assays) establishing mechanism of BCLAF1 in IFN signaling","pmids":["30682178"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of SDS22 reveals a large basic surface patch that enables binding of a phosphorylated form of splicing factor BCLAF1. Biochemical studies show SDS22 acts as a 'third' subunit of multiple PP1 holoenzymes and recruits phospho-BCLAF1.","method":"X-ray crystallography (SDS22 structure), biochemical binding assays, modeling","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with biochemical validation; interaction is structural and biochemically confirmed, single lab","pmids":["30661852"],"is_preprint":false},{"year":2019,"finding":"RAG DNA double-strand breaks in pre-B cells activate a SPIC/BCLAF1 transcription factor complex. SPIC recruits BCLAF1 to gene-regulatory elements controlling expression of key B cell developmental genes. The SPIC/BCLAF1 complex suppresses SYK tyrosine kinase expression and enforces the transition from large to small pre-B cells.","method":"Co-immunoprecipitation, ChIP-seq, gene expression analysis, B cell developmental assays in pre-B cell models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus ChIP-seq with functional developmental readout, multiple orthogonal methods","pmids":["31644907"],"is_preprint":false},{"year":2020,"finding":"BCLAF1 is a direct transcriptional target of HIF-1 and is upregulated during hypoxia. BCLAF1 binds HIF-1α in the nucleus, and this interaction is required for BCLAF1 to stabilize HIF-1α during long-term hypoxia. BCLAF1 knockout cells show greatly reduced HIF-1α protein stability and impaired induction of HIF-1 target gene transcription after prolonged hypoxia.","method":"ChIP (HIF-1 binding to BCLAF1 promoter), Co-immunoprecipitation (BCLAF1-HIF-1α), CRISPR knockout, HIF-1α stability assays, xenograft tumor model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, Co-IP, and CRISPR knockout with in vivo validation; multiple orthogonal methods in one study","pmids":["32029898"],"is_preprint":false},{"year":2021,"finding":"BCLAF1 exerts anti-apoptotic function in TNF signaling by promoting transcription of CFLAR (encoding c-FLIP, a caspase 8 antagonist) downstream of NF-κB activation. BCLAF1 binds to the p50 subunit of NF-κB, which is required for BCLAF1 to stimulate CFLAR transcription. BCLAF1 depletion sensitizes cells to TNF-induced apoptosis but not necroptosis, and exacerbates TNF-induced small intestine injury in mice.","method":"Co-immunoprecipitation (BCLAF1-p50 interaction), siRNA knockdown, reporter assay, apoptosis/necroptosis assays, in vivo mouse model (siRNA administration)","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifying binding partner, reporter assay for mechanism, and in vivo validation with multiple orthogonal methods","pmids":["34693625"],"is_preprint":false},{"year":2021,"finding":"lncCIRBIL directly binds to BCLAF1 protein and inhibits its nuclear translocation. Cardiomyocyte-specific Bclaf1 overexpression worsens cardiac I/R injury, while partial Bclaf1 knockout mitigates it. Partial Bclaf1 knockout abrogates the detrimental effects of lncCIRBIL knockout, placing Bclaf1 downstream of lncCIRBIL in cardiac I/R injury.","method":"RNA-protein binding assay (lncCIRBIL-BCLAF1 interaction), nuclear translocation assay, transgenic overexpression and knockout mice, I/R injury model","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated with localization and genetic epistasis in vivo; regulatory relationship is lncRNA-protein so some indirection, single lab","pmids":["33483496"],"is_preprint":false},{"year":2021,"finding":"ATM activation in response to ionizing radiation leads to BCLAF1-dependent regulation of PD-L1 stability. BCLAF1 depletion decreases PD-L1 expression by promoting its ubiquitination. CMTM6 is upregulated in response to IR and participates in BCLAF1-dependent PD-L1 upregulation. The ATM/BCLAF1/PD-L1 axis was identified by mass spectrometry and validated by co-immunoprecipitation.","method":"Mass spectrometry (PD-L1 interactome), co-immunoprecipitation, ubiquitination assay, siRNA knockdown, T cell co-culture assay","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-identified interaction validated by Co-IP and ubiquitination assay, single lab","pmids":["34251713"],"is_preprint":false},{"year":2022,"finding":"TET2 and BCLAF1 form a transcription repression complex in CRC cells. The TET2-BCLAF1 complex binds multiple elements around CCGG sites at the Ascl2 promoter and restrains its hypermethylation by inducing hydroxymethylation. BCLAF1 was identified as a TET2 interactor by LC-MS/MS and validated by co-immunoprecipitation, immunofluorescence co-localization, and proximity ligation assays.","method":"LC-MS/MS, co-immunoprecipitation, immunofluorescence co-localization, proximity ligation assay, ChIP-qPCR, glucosylated hydroxymethyl-qPCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — MS identification validated by four orthogonal interaction assays plus ChIP-qPCR for functional chromatin binding","pmids":["35660018"],"is_preprint":false},{"year":2022,"finding":"BCLAF1 physically interacts with SPOP (an E3 ubiquitin ligase) via an SPOP-binding consensus (SBC) motif on BCLAF1, competitively inhibiting SPOP-PD-L1 interaction and subsequent ubiquitination and degradation of PD-L1. Mutation of the BCLAF1-SBC motif disrupts regulation of the SPOP-PD-L1 axis.","method":"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis of SBC motif, T cell co-culture model, in vitro competition assay","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP with mutagenesis validation and functional ubiquitination assay with T cell readout","pmids":["38340178"],"is_preprint":false},{"year":2022,"finding":"BCLAF1 silencing in smooth muscle cells (SMCs) led to downregulation of BCL2 and SMC markers, reduced proliferation, and increased apoptosis. oxLDL-induced transdifferentiation of SMCs was accompanied by BCLAF1 upregulation, and BCLAF1 silencing during oxLDL exposure preserved MYH11 expression and prevented SMC transdifferentiation. BCLAF1 was shown to interact with BCL2 by proximity ligation assay in plaque cells.","method":"siRNA knockdown, proximity ligation assay (BCLAF1-BCL2 interaction), oxLDL treatment, immunohistochemistry, lineage-tracing mouse model","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity ligation for interaction plus functional knockdown; in vivo lineage tracing adds context, single lab","pmids":["35321563"],"is_preprint":false},{"year":2022,"finding":"BCLAF1 was identified as a binding partner of BACH1 by tandem protein affinity purification. BCLAF1 constitutively interacts with BACH1 regardless of DNA damage, but in response to DNA damage, BCLAF1 is recruited to DNA damage sites in a BACH1- and BRCA1-dependent manner. BCLAF1-deficient cells are defective for DSB-initiated homologous recombination, but RAD51 foci formation is intact.","method":"Tandem protein affinity purification, co-immunoprecipitation, recruitment to DNA damage sites (foci assay), HR repair assay, RAD51 foci assay","journal":"DNA repair","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity purification and Co-IP with mechanistic HR assay, single lab","pmids":["35930920"],"is_preprint":false},{"year":2023,"finding":"Cross-linking mass spectrometry (XL-MS) of endogenous protein complexes identified crosslinks between BCLAF1, THRAP3, and ERH, mapping interaction surfaces to non-disordered portions of both BCLAF1 and THRAP3, suggesting these three proteins form a novel complex (TEB complex).","method":"Cross-linking mass spectrometry (XL-MS with DSSO crosslinker) after immunoprecipitation of endogenous complexes","journal":"Wellcome open research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structural interaction mapping via XL-MS of endogenous proteins, single lab, no functional validation of complex","pmids":["35865489"],"is_preprint":false},{"year":2023,"finding":"BCLAF1 promotes HIF-1α accumulation under normoxia by interacting with CUL3 (Cullin 3) ubiquitin ligase, promoting ubiquitination and degradation of PHD2 (prolyl hydroxylase domain protein 2), thereby stabilizing HIF-1α. This leads to HIF-1α-dependent PD-L1 transcription. BCLAF1-CUL3 interaction validated by co-immunoprecipitation and immunofluorescence.","method":"Co-immunoprecipitation, immunofluorescence, PHD2 ubiquitination assay, Western blot, RT-qPCR","journal":"Cancer immunology, immunotherapy : CII","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ubiquitination assay, single lab, mechanistic cascade supported by multiple assays","pmids":["37906282"],"is_preprint":false},{"year":2024,"finding":"BCLAF1 interacts with YTHDF2 (an m6A reader) in ESCC cells, reducing YTHDF2's tumor-suppressive activities. BCLAF1-YTHDF2 interaction was validated by mass spectrometry, co-localization, co-immunoprecipitation, and GST pull-down. This interaction leads to stabilization of SIX1 mRNA (normally degraded by YTHDF2), promoting glycolysis and cancer progression in an m6A-specific manner.","method":"Mass spectrometry, co-immunoprecipitation, GST pull-down, MeRIP-seq, RIP-seq, transcriptomic analysis","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 2 / Strong — interaction identified by MS and validated by three orthogonal methods (Co-IP, GST pull-down, co-localization) plus mechanism established by MeRIP-seq and RIP-seq","pmids":["38636894"],"is_preprint":false},{"year":2024,"finding":"BCLAF1 interacts with LAMTOR2, and LAMTOR2 regulates the nuclear translocation of BCLAF1 in chondrocytes. BCLAF1 knockdown inhibits catabolic factor expression and apoptosis in chondrocytes while promoting anabolic factors, and intra-articular injection of Bclaf1 shRNA attenuates OA cartilage degradation in mice.","method":"Immunoprecipitation, protein mass spectrometry, nuclear translocation assay, siRNA/shRNA knockdown, overexpression, in vivo mouse OA model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IP-MS identification of LAMTOR2 with nuclear translocation assay and in vivo functional validation, single lab","pmids":["39990659"],"is_preprint":false},{"year":2024,"finding":"MED23 physically interacts with BCLAF1 in NSCLC cells, as identified by co-IP and mass spectrometry (validated by PLA assays). The MED23/BCLAF1 complex regulates transcription of NUPR1, which controls autophagic flux; loss of MED23 reduces NUPR1 expression and triggers premature senescence.","method":"Co-immunoprecipitation, mass spectrometry, proximity ligation assay, RNA-seq, ChIP assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-identified interaction validated by PLA and ChIP-confirmed target gene regulation, single lab","pmids":["39366174"],"is_preprint":false},{"year":2025,"finding":"BCKDK phosphorylates BCLAF1 at serine 285, facilitating BCLAF1 binding to the MYC promoter and enhancing MYC transcription in lung cancer cells. Elevated MYC then upregulates hexokinase 2 (HK2), promoting aerobic glycolysis and Trametinib resistance. BCKDK-BCLAF1 interaction was identified through molecular biology experiments.","method":"Co-immunoprecipitation, phosphorylation assay (S285 site), ChIP (BCLAF1 at MYC promoter), site-directed mutagenesis, functional glycolysis assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus phosphorylation site identification and ChIP supporting mechanistic model, single lab","pmids":["40442441"],"is_preprint":false},{"year":2025,"finding":"Nuclear p85β physically interacts with BCLAF1 and shows genome-wide co-occupancy at gene targets. BCLAF1 recruits p85β to BCLAF1 gene loci, and p85β facilitates assembly of a complex containing BCLAF1, TRIM28, and ZNF263, which together activate BCLAF1 transcription (positive autoregulation). Multi-omics analysis confirmed physical interaction and functional cooperativity.","method":"Co-immunoprecipitation, ChIP-seq (co-occupancy), RNA-seq, multi-omics approach","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP validated by ChIP-seq co-occupancy with multi-omics functional cooperativity, multiple orthogonal methods","pmids":["40016211"],"is_preprint":false},{"year":2025,"finding":"BCLAF1 physically associates with core spliceosome components and regulates alternative splicing with a predominant effect on intron retention. BCLAF1 is required for productive splicing of ATF4 mRNA to sustain ATF4 protein expression and downstream metabolic gene regulation. Loss of BCLAF1 reduces ATF4 protein levels, disrupts de novo amino acid biosynthesis, and sensitizes AML cells to venetoclax.","method":"Co-immunoprecipitation (spliceosome components), RNA-seq/alternative splicing analysis, ATF4 protein/mRNA assays, metabolomics, venetoclax sensitivity assay","journal":"bioRxiv : the preprint server for biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with spliceosome, splicing analysis, and mechanistic downstream validation; preprint, single lab","pmids":["41648520"],"is_preprint":true},{"year":2025,"finding":"Bclaf1 undergoes liquid-liquid phase separation (LLPS) to form nuclear biomolecular condensates during oxidative stress in cardiomyocytes. PTK2 sequestered within Bclaf1 condensates is protected from ubiquitin-proteasome-mediated degradation at lysine 926. Disruption of Bclaf1 condensates leads to PTK2 degradation, increased p53 levels, and increased apoptosis.","method":"Advanced microscopy (LLPS/condensate visualization), ubiquitination assay, proteasome inhibition, site-directed mutagenesis (K926), Bclaf1 knockdown with apoptosis readout","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — LLPS and ubiquitination site identified with functional consequence; preprint, single lab, novel finding needing peer review","pmids":["bio_10.1101_2025.02.04.636487"],"is_preprint":true},{"year":2025,"finding":"BCLAF1 promotes chromatin accessibility in esophageal carcinoma by activating POLR2A (RNA polymerase II subunit) through two mechanisms: (1) transcriptional activation via co-recruitment of BCLAF1/P300/H3K27ac at the POLR2A super-enhancer (E2/E3 elements), and (2) splicing regulation of pre-POLR2A mRNA through interaction with SNRPA (small nuclear ribonucleoprotein polypeptide A).","method":"ATAC-seq (chromatin accessibility), CUT&Tag (co-occupancy at POLR2A super-enhancer), RNA-binding protein immunoprecipitation (RIP) for SNRPA interaction, siRNA knockdown, in vitro and in vivo models","journal":"Journal of hazardous materials","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CUT&Tag and RIP establish dual mechanism with ATAC-seq phenotype, single lab","pmids":["40220379"],"is_preprint":false},{"year":2025,"finding":"BCLAF1 restrains stress response gene expression in hematopoietic stem cells (HSCs) and promotes HSC repopulation activity. BCLAF1 associates with chromatin throughout the genome of fetal and adult hematopoietic cells to regulate transcriptional programs. Loss of BCLAF1 impairs HSC self-renewal and multilineage reconstitution after stem cell transplantation.","method":"Hematopoietic-specific and inducible deletion (Cre-lox), single-cell RNA-seq, chromatin association assay, stem cell transplantation/reconstitution assay","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with scRNA-seq and chromatin association data plus functional transplantation assay, multiple orthogonal methods","pmids":["40435510"],"is_preprint":false}],"current_model":"BCLAF1 is a multifunctional nuclear protein that (1) represses transcription by binding DNA via its bZIP and Myb-like domains, with anti-apoptotic Bcl-2 family members sequestering it in the cytoplasm to block this activity; (2) regulates alternative splicing and mRNA nuclear export as an SR-like splicing factor that associates with spliceosome components and the exon junction complex; (3) participates in the DNA damage response by interacting with γH2AX, stabilizing the Ku70/DNA-PKcs NHEJ complex, and acting as a functional partner of BACH1 for homologous recombination; (4) transduces NF-κB signaling to C/EBPβ during senescence and promotes c-FLIP transcription downstream of NF-κB to protect against TNF-induced apoptosis; (5) stabilizes HIF-1α protein in the nucleus under hypoxia, driving a positive HIF-1/BCLAF1 feedback loop and promoting angiogenesis; (6) interacts with SPOP and CUL3 to regulate PD-L1 stability via the ubiquitin-proteasome system; (7) forms condensates that protect binding partners (e.g., PTK2) from proteasomal degradation; and (8) is itself regulated post-translationally by PKCδ-mediated activation, BCKDK-mediated phosphorylation at S285, SDS22-recruited PP1 (via phospho-BCLAF1), and by viral factors (HCMV pp71/UL35 proteasomal degradation, HSV-1/PRV US3 degradation) that neutralize its antiviral restriction activity."},"narrative":{"mechanistic_narrative":"BCLAF1 is a multifunctional nuclear protein that integrates transcriptional regulation, RNA processing, and stress signaling to control cell fate decisions across development, immunity, and tumorigenesis [PMID:10330179, PMID:19008920, PMID:40435510]. It was originally identified as a DNA-binding transcriptional repressor sequestered in the cytoplasm by anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL, E1B 19K), with sustained overexpression driving apoptosis [PMID:10330179]. As a chromatin-associated factor it occupies target promoters in partnership with diverse transcription factors and cofactors: it co-occupies the TP53 promoter with PKCδ to drive p53-dependent apoptosis [PMID:17938203], cooperates with C/EBPβ and NF-κB subunits (p65/c-Rel during senescence, p50 to induce the caspase-8 antagonist c-FLIP) [PMID:26794446, PMID:34693625], partners with SPIC to enforce pre-B cell development [PMID:31644907], forms a repressive complex with TET2 to control DNA methylation at target loci [PMID:35660018], and positively autoregulates its own transcription via a complex with p85β, TRIM28, and ZNF263 [PMID:40016211]. In parallel, BCLAF1 functions as an SR-like splicing and mRNA-export factor that associates with the exon junction complex and core spliceosome and, together with THRAP3, controls splicing and nuclear export of DNA-damage-response transcripts including ATM mRNA, thereby safeguarding genome stability [PMID:23778535, PMID:29112714, PMID:41648520]. It additionally participates directly in DNA repair by associating with γH2AX, stabilizing the Ku70/DNA-PKcs NHEJ complex, and acting as a BACH1- and BRCA1-dependent partner in homologous recombination [PMID:22833098, PMID:35930920]. BCLAF1 is a transcriptional target and stabilizer of HIF-1α under hypoxia, forming a positive feedback loop that drives angiogenesis and, via CUL3-dependent PHD2 degradation, sustains HIF-1α and PD-L1 even under normoxia [PMID:30367150, PMID:32029898, PMID:37906282]. Its activity is tuned post-translationally by PKCδ, BCKDK-mediated phosphorylation at Ser285 (promoting MYC transcription and glycolysis), and phospho-dependent recruitment of PP1 via SDS22, and its nuclear translocation is gated by LAMTOR2 and lncCIRBIL [PMID:17938203, PMID:40442441, PMID:30661852, PMID:39990659, PMID:33483496]. BCLAF1 acts as a restriction factor against cytomegalovirus and alphaherpesviruses and supports type I interferon signaling by maintaining STAT phosphorylation and ISGF3 promoter binding; viral proteins (HCMV pp71/UL35, HSV-1/PRV US3) neutralize it by proteasomal degradation [PMID:22645331, PMID:30682178]. In vivo, BCLAF1 is required for lung smooth muscle organization, peripheral T-cell homeostasis, and hematopoietic stem cell self-renewal, with knockout cells showing no intrinsic apoptosis defect, refining its originally postulated proapoptotic role [PMID:19008920, PMID:40435510].","teleology":[{"year":1999,"claim":"Established BCLAF1's founding identity as a DNA-binding transcriptional repressor whose activity is held in check by anti-apoptotic Bcl-2 proteins, linking it to apoptotic control.","evidence":"Yeast two-hybrid screen, in vitro DNA binding, reporter assay, and overexpression apoptosis assay in HeLa cells","pmids":["10330179"],"confidence":"High","gaps":["Direct DNA target sequences and endogenous repressed genes not defined","Whether apoptosis is a physiological function untested in vivo at this stage"]},{"year":2004,"claim":"Mapped a high-affinity emerin interaction and showed apoptosis-regulated relocalization, tying BCLAF1 to the nuclear envelope and a disease-relevant mutation.","evidence":"Equilibrium binding assay, alanine-scanning mutagenesis, and immunofluorescence in HeLa cells","pmids":["15009215"],"confidence":"High","gaps":["Functional consequence of emerin binding for BCLAF1 activity not established","Significance of nuclear-interior dot localization unresolved"]},{"year":2007,"claim":"Defined a concrete transcriptional target and upstream kinase by showing PKCδ interacts with BCLAF1 to co-occupy and activate the TP53 promoter, enabling genotoxic stress apoptosis.","evidence":"Co-IP, ChIP co-occupancy at CPE-TP53, reporter assay, and RNAi with apoptosis readout","pmids":["17938203"],"confidence":"High","gaps":["Whether PKCδ directly phosphorylates BCLAF1 not shown","Broader PKCδ-dependent target gene set undefined"]},{"year":2008,"claim":"Revealed BCLAF1's essential developmental and immune roles in vivo and overturned the assumption that it is intrinsically proapoptotic.","evidence":"Targeted knockout mice with lung developmental and T-cell compartment analysis","pmids":["19008920"],"confidence":"High","gaps":["Molecular mechanism behind lung and T-cell phenotypes not defined","Reconciliation with cell-line proapoptotic data left open"]},{"year":2011,"claim":"Placed BCLAF1 under NF-κB/Sirt1-controlled epigenetic regulation, showing its expression is dynamically gated during T-cell activation.","evidence":"ChIP, Co-IP, histone H3K56 acetylation analysis, and siRNA in T cells","pmids":["21454709"],"confidence":"High","gaps":["Direct BCLAF1 effector genes in activated T cells not identified","Whether BCLAF1 feeds back on NF-κB unaddressed at this stage"]},{"year":2012,"claim":"Connected BCLAF1 to the DNA damage response and to viral restriction, establishing dual roles in NHEJ-based repair and innate antiviral defense.","evidence":"Co-IP, γH2AX co-localization and NHEJ assays; viral degradation and replication assays for HCMV","pmids":["22833098","22645331"],"confidence":"High","gaps":["Mechanism by which BCLAF1 stabilizes Ku70/DNA-PKcs not structurally defined","How tumor cells suppress BCLAF1 unresolved"]},{"year":2013,"claim":"Defined BCLAF1 as an RNA-processing factor at active transcription loci that restricts mRNA nuclear export, distinguishing it functionally from its paralog TRAP150.","evidence":"Reporter-locus microscopy, EJC (Magoh) overlap, siRNA, and nuclear/cytoplasmic fractionation with RT-PCR","pmids":["23778535"],"confidence":"Medium","gaps":["Direct RNA substrates not catalogued","Molecular basis of export restriction unknown"]},{"year":2014,"claim":"Showed BCLAF1 is itself a splicing-regulated gene whose SRSF10-driven exon5a isoform has oncogenic activity, linking its isoform identity to tumor phenotypes.","evidence":"Splicing assay, siRNA, overexpression, and tumorigenicity assays in colorectal cancer cells","pmids":["25091051"],"confidence":"High","gaps":["Functional difference between isoforms at the protein level not defined","Whether isoform switching alters partner binding unknown"]},{"year":2016,"claim":"Defined BCLAF1 as an NF-κB-induced transducer to C/EBPβ during therapy-induced senescence, controlling SASP cytokine output and tumor suppression.","evidence":"ChIP, Co-IP with C/EBPβ leucine zipper, reporter assay, siRNA, and xenograft model","pmids":["26794446"],"confidence":"High","gaps":["Whether BCLAF1 acts as transcription factor or cofactor at IL-6/IL-8 loci not fully resolved","Generality across senescence triggers untested"]},{"year":2017,"claim":"Established a unifying mechanism whereby BCLAF1/THRAP3 control DDR via selective splicing and export of repair transcripts, and linked BCLAF1 to mitotic transcript control.","evidence":"siRNA, DNA damage sensitivity and repair assays, splicing/export analysis, and mitotic phenotype/RT-PCR readouts","pmids":["29112714","28895891"],"confidence":"High","gaps":["RNA-binding specificity determinants not defined","Direct versus indirect effects on mitotic regulators unresolved"]},{"year":2018,"claim":"Identified a HIF-1α/BCLAF1 positive feedback loop and a Cry2-coupled mRNA-stabilizing function, expanding BCLAF1's roles into hypoxic angiogenesis and circadian myogenesis.","evidence":"shRNA, reporter and bZIP domain-deletion assays, xenograft for HIF1A; Co-IP, mRNA stability assays and Cry2 KO mice for circadian function","pmids":["30367150","29466738"],"confidence":"High","gaps":["How BCLAF1 stabilizes HIF-1α mechanistically not yet defined at this stage","Determinants of Cry2-selective mRNA targeting unknown"]},{"year":2019,"claim":"Defined BCLAF1 as a STAT/ISGF3-supporting interferon effector, a SPIC-recruited B-cell developmental regulator, and a phospho-dependent PP1 substrate, broadening its signaling and post-translational regulatory repertoire.","evidence":"Co-IP, ChIP/DNA binding, CRISPR KO and antiviral assays (IFN); Co-IP and ChIP-seq (SPIC); X-ray crystallography of SDS22 with phospho-BCLAF1 binding","pmids":["30682178","31644907","30661852"],"confidence":"High","gaps":["Phosphosites recognized by SDS22/PP1 not mapped at this stage","How US3 selects BCLAF1 for degradation unknown"]},{"year":2020,"claim":"Resolved the HIF-1α stabilization mechanism by showing nuclear BCLAF1 binds HIF-1α directly and is required to sustain it during prolonged hypoxia.","evidence":"ChIP, Co-IP, CRISPR knockout, HIF-1α stability assays, and xenograft model","pmids":["32029898"],"confidence":"High","gaps":["Biochemical basis of HIF-1α protection by BCLAF1 not fully defined","Whether stabilization requires BCLAF1 chromatin function unresolved"]},{"year":2021,"claim":"Established BCLAF1 as an NF-κB-p50-dependent anti-apoptotic transcriptional driver of c-FLIP and as a lncRNA-gated mediator of cardiac injury, refining its context-dependent cell-death roles.","evidence":"Co-IP with p50, reporter assay, apoptosis/necroptosis assays and intestinal injury model (CFLAR); RNA-protein binding, nuclear translocation, and transgenic I/R models (lncCIRBIL)","pmids":["34693625","33483496"],"confidence":"High","gaps":["How the same protein switches between pro- and anti-apoptotic outputs not unified","lncCIRBIL binding site on BCLAF1 not mapped"]},{"year":2021,"claim":"Linked ATM-activated BCLAF1 to PD-L1 stability, implicating BCLAF1 in immune evasion downstream of DNA damage.","evidence":"Mass spectrometry, Co-IP, ubiquitination assay, siRNA, and T-cell co-culture","pmids":["34251713"],"confidence":"Medium","gaps":["Direct mechanism by which BCLAF1 protects PD-L1 from ubiquitination unclear","Single-lab MS-based interaction"]},{"year":2022,"claim":"Expanded BCLAF1's interactome and PD-L1 regulation, revealing TET2 repressive complex formation, BACH1/BRCA1-dependent HR, competitive SPOP inhibition stabilizing PD-L1, and a BCL2-linked smooth-muscle role.","evidence":"LC-MS/MS, Co-IP, PLA and ChIP (TET2); affinity purification and HR assays (BACH1); SBC-motif mutagenesis and ubiquitination assays (SPOP); siRNA, PLA and lineage tracing (BCL2/SMC)","pmids":["35660018","35930920","38340178","35321563"],"confidence":"High","gaps":["How BCLAF1 partitions among these complexes within a cell unknown","Stoichiometry and mutual exclusivity of partners undefined"]},{"year":2023,"claim":"Structurally placed BCLAF1 in a defined TEB complex with THRAP3 and ERH and resolved an alternate normoxic HIF-1α stabilization route via CUL3-dependent PHD2 degradation.","evidence":"Cross-linking mass spectrometry of endogenous complexes (TEB); Co-IP, immunofluorescence and PHD2 ubiquitination assays (CUL3)","pmids":["35865489","37906282"],"confidence":"Medium","gaps":["Functional role of the TEB complex not tested","Whether CUL3-PHD2 and direct HIF-1α binding mechanisms coexist or compete unresolved"]},{"year":2024,"claim":"Connected BCLAF1 to m6A-RNA metabolism via YTHDF2 antagonism and to lysosomal/mTOR-adjacent signaling via LAMTOR2-gated nuclear translocation, expanding its post-transcriptional and localization control.","evidence":"MS, Co-IP, GST pull-down, MeRIP/RIP-seq (YTHDF2); IP-MS, nuclear translocation, knockdown and OA model (LAMTOR2)","pmids":["38636894","39990659"],"confidence":"High","gaps":["Whether BCLAF1 alters YTHDF2 catalytic engagement or sequesters it not distinguished","How LAMTOR2 controls BCLAF1 import mechanistically unknown"]},{"year":2025,"claim":"Defined upstream phospho-control by BCKDK at Ser285 and a cofactor partnership with MED23, linking BCLAF1 to MYC-driven glycolysis, drug resistance, and autophagy/senescence transcriptional programs.","evidence":"Co-IP, S285 phosphorylation assay, ChIP and glycolysis assays (BCKDK/MYC); Co-IP, PLA, RNA-seq and ChIP (MED23/NUPR1)","pmids":["40442441","39366174"],"confidence":"Medium","gaps":["How Ser285 phosphorylation alters BCLAF1 DNA binding biochemically unresolved","Single-lab studies awaiting independent confirmation"]},{"year":2025,"claim":"Established BCLAF1's autoregulatory transcription circuit, its requirement for HSC self-renewal, and a dual transcription/splicing mechanism controlling POLR2A and chromatin accessibility.","evidence":"Co-IP and ChIP-seq with p85β/TRIM28/ZNF263 (autoregulation); conditional KO, scRNA-seq and transplantation (HSC); ATAC-seq, CUT&Tag and RIP with SNRPA (POLR2A)","pmids":["40016211","40435510","40220379"],"confidence":"High","gaps":["How autoregulation is set or reset across cell states unknown","Whether the POLR2A dual mechanism generalizes beyond esophageal carcinoma untested"]},{"year":2025,"claim":"Proposed condensate-based and splicing-based protective mechanisms, with BCLAF1 phase separation shielding PTK2 from degradation and BCLAF1-dependent ATF4 splicing sustaining amino-acid metabolism.","evidence":"LLPS imaging, ubiquitination and K926 mutagenesis assays (PTK2, preprint); Co-IP with spliceosome, splicing analysis, metabolomics and venetoclax sensitivity (ATF4, preprint)","pmids":["bio_10.1101_2025.02.04.636487","41648520"],"confidence":"Medium","gaps":["Both findings are preprints awaiting peer review","Determinants of BCLAF1 condensate formation and client selection not defined"]},{"year":null,"claim":"It remains unresolved how a single protein coordinates its DNA-binding/transcription, splicing/export, DNA-repair, and condensate functions, and what determines its partitioning among the many mutually exclusive partner complexes and post-translational states.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of full-length BCLAF1 or its domain-specific partner engagement","Rules governing context-dependent pro- versus anti-apoptotic outputs unknown","Whether splicing, transcription, and condensate roles are temporally or spatially separated undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,14]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,9,16,21,31]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[7,10,13,27,32]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[10,32,34]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[12,17,22,26]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,7,17,35]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[7,31,33]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[16,21,31,34,35]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,9,16,21,31]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[7,10,13,27,32]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[5,10,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,14,16,35]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[9,12,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,5,18]}],"complexes":["TEB complex (BCLAF1-THRAP3-ERH)","SPIC/BCLAF1 transcription complex","TET2-BCLAF1 repression complex","Ku70/DNA-PKcs NHEJ complex"],"partners":["THRAP3","HIF1A","BACH1","TET2","SPOP","CUL3","C/EBPΒ","YTHDF2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NYF8","full_name":"Bcl-2-associated transcription factor 1","aliases":["BCLAF1 and THRAP3 family member 1"],"length_aa":920,"mass_kda":106.1,"function":"Death-promoting transcriptional repressor. May be involved in cyclin-D1/CCND1 mRNA stability through the SNARP complex which associates with both the 3'end of the CCND1 gene and its mRNA","subcellular_location":"Cytoplasm; Nucleus; Nucleus speckle; Nucleus, nucleoplasm","url":"https://www.uniprot.org/uniprotkb/Q9NYF8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BCLAF1","classification":"Common Essential","n_dependent_lines":1028,"n_total_lines":1208,"dependency_fraction":0.8509933774834437},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PRPF4B","stoichiometry":4.0},{"gene":"SSRP1","stoichiometry":4.0},{"gene":"TOP1","stoichiometry":4.0},{"gene":"CD2BP2","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"DDX21","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"RBM39","stoichiometry":0.2},{"gene":"RNF40","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BCLAF1","total_profiled":1310},"omim":[{"mim_id":"616731","title":"NIMA-RELATED KINASE 5; NEK5","url":"https://www.omim.org/entry/616731"},{"mim_id":"616453","title":"ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 13; ZC3H13","url":"https://www.omim.org/entry/616453"},{"mim_id":"616447","title":"VIR-LIKE M6A METHYLTRANSFERASE-ASSOCIATED PROTEIN; VIRMA","url":"https://www.omim.org/entry/616447"},{"mim_id":"612588","title":"BCL2-ASSOCIATED TRANSCRIPTION FACTOR 1; BCLAF1","url":"https://www.omim.org/entry/612588"},{"mim_id":"606872","title":"CAS-BR-M MURINE ECTOPIC RETROVIRAL TRANSFORMING SEQUENCE LIKE-1; CBLL1","url":"https://www.omim.org/entry/606872"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nuclear speckles","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":127.3}],"url":"https://www.proteinatlas.org/search/BCLAF1"},"hgnc":{"alias_symbol":["KIAA0164","BTF"],"prev_symbol":[]},"alphafold":{"accession":"Q9NYF8","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYF8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYF8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NYF8-F1-predicted_aligned_error_v6.png","plddt_mean":46.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCLAF1","jax_strain_url":"https://www.jax.org/strain/search?query=BCLAF1"},"sequence":{"accession":"Q9NYF8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NYF8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NYF8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NYF8"}},"corpus_meta":[{"pmid":"10330179","id":"PMC_10330179","title":"Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10330179","citation_count":179,"is_preprint":false},{"pmid":"25091051","id":"PMC_25091051","title":"BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25091051","citation_count":152,"is_preprint":false},{"pmid":"15009215","id":"PMC_15009215","title":"Emerin binding to Btf, a death-promoting transcriptional repressor, is disrupted by a missense mutation that causes Emery-Dreifuss muscular dystrophy.","date":"2004","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15009215","citation_count":126,"is_preprint":false},{"pmid":"17938203","id":"PMC_17938203","title":"Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17938203","citation_count":95,"is_preprint":false},{"pmid":"30367150","id":"PMC_30367150","title":"Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30367150","citation_count":94,"is_preprint":false},{"pmid":"29112714","id":"PMC_29112714","title":"The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29112714","citation_count":87,"is_preprint":false},{"pmid":"21454709","id":"PMC_21454709","title":"The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21454709","citation_count":82,"is_preprint":false},{"pmid":"22833098","id":"PMC_22833098","title":"BCLAF1 is a radiation-induced H2AX-interacting partner involved in γH2AX-mediated regulation of apoptosis and DNA repair.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22833098","citation_count":81,"is_preprint":false},{"pmid":"19008920","id":"PMC_19008920","title":"Essential role for Bclaf1 in lung development and immune system function.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19008920","citation_count":71,"is_preprint":false},{"pmid":"28216661","id":"PMC_28216661","title":"miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28216661","citation_count":67,"is_preprint":false},{"pmid":"22645331","id":"PMC_22645331","title":"BclAF1 restriction factor is neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22645331","citation_count":66,"is_preprint":false},{"pmid":"35882275","id":"PMC_35882275","title":"Curcumin induces mitochondrial apoptosis in human hepatoma cells through BCLAF1-mediated modulation of PI3K/AKT/GSK-3β signaling.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35882275","citation_count":60,"is_preprint":false},{"pmid":"26794446","id":"PMC_26794446","title":"Bclaf1 is an important NF-κB signaling transducer and C/EBPβ regulator in DNA damage-induced senescence.","date":"2016","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26794446","citation_count":58,"is_preprint":false},{"pmid":"20661537","id":"PMC_20661537","title":"In search of a function for BCLAF1.","date":"2010","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/20661537","citation_count":56,"is_preprint":false},{"pmid":"29466738","id":"PMC_29466738","title":"Cry2 Is Critical for Circadian Regulation of Myogenic Differentiation by Bclaf1-Mediated mRNA Stabilization of Cyclin D1 and Tmem176b.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29466738","citation_count":55,"is_preprint":false},{"pmid":"30682178","id":"PMC_30682178","title":"Bclaf1 critically regulates the type I interferon response and is degraded by alphaherpesvirus US3.","date":"2019","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/30682178","citation_count":52,"is_preprint":false},{"pmid":"33483496","id":"PMC_33483496","title":"The long noncoding RNA lncCIRBIL disrupts the nuclear translocation of Bclaf1 alleviating cardiac ischemia-reperfusion injury.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33483496","citation_count":52,"is_preprint":false},{"pmid":"26676636","id":"PMC_26676636","title":"Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26676636","citation_count":49,"is_preprint":false},{"pmid":"31870774","id":"PMC_31870774","title":"BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31870774","citation_count":45,"is_preprint":false},{"pmid":"19705920","id":"PMC_19705920","title":"The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells.","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19705920","citation_count":45,"is_preprint":false},{"pmid":"36522479","id":"PMC_36522479","title":"Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36522479","citation_count":39,"is_preprint":false},{"pmid":"33363466","id":"PMC_33363466","title":"Ginsenoside Compound K Regulates HIF-1α-Mediated Glycolysis Through Bclaf1 to Inhibit the Proliferation of Human Liver Cancer Cells.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33363466","citation_count":39,"is_preprint":false},{"pmid":"34992690","id":"PMC_34992690","title":"Function of BCLAF1 in human disease.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34992690","citation_count":37,"is_preprint":false},{"pmid":"33188158","id":"PMC_33188158","title":"LncRNA PVT1 accelerates malignant phenotypes of bladder cancer cells by modulating miR-194-5p/BCLAF1 axis as a ceRNA.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33188158","citation_count":33,"is_preprint":false},{"pmid":"38340178","id":"PMC_38340178","title":"BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38340178","citation_count":29,"is_preprint":false},{"pmid":"32029898","id":"PMC_32029898","title":"Bclaf1 is a direct target of HIF-1 and critically regulates the stability of HIF-1α under hypoxia.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32029898","citation_count":23,"is_preprint":false},{"pmid":"35321563","id":"PMC_35321563","title":"Plaque Evaluation by Ultrasound and Transcriptomics Reveals BCLAF1 as a Regulator of Smooth Muscle Cell Lipid Transdifferentiation in Atherosclerosis.","date":"2022","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35321563","citation_count":22,"is_preprint":false},{"pmid":"23778535","id":"PMC_23778535","title":"Btf and TRAP150 have distinct roles in regulating subcellular mRNA distribution.","date":"2013","source":"Nucleus (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23778535","citation_count":21,"is_preprint":false},{"pmid":"32968449","id":"PMC_32968449","title":"BCLAF1 induces cisplatin resistance in lung cancer cells.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32968449","citation_count":21,"is_preprint":false},{"pmid":"38805063","id":"PMC_38805063","title":"CircZFR promotes colorectal cancer progression via stabilizing BCLAF1 and regulating the miR-3127-5p/RTKN2 axis.","date":"2024","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38805063","citation_count":19,"is_preprint":false},{"pmid":"29969367","id":"PMC_29969367","title":"Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29969367","citation_count":19,"is_preprint":false},{"pmid":"38878918","id":"PMC_38878918","title":"Transfer of miR-877-3p via extracellular vesicles derived from dental pulp stem cells attenuates neuronal apoptosis and facilitates early neurological functional recovery after cerebral ischemia-reperfusion injury through the Bclaf1/P53 signaling pathway.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/38878918","citation_count":18,"is_preprint":false},{"pmid":"31644907","id":"PMC_31644907","title":"RAG-Mediated DNA Breaks Attenuate PU.1 Activity in Early B Cells through Activation of a SPIC-BCLAF1 Complex.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31644907","citation_count":18,"is_preprint":false},{"pmid":"34693625","id":"PMC_34693625","title":"Bclaf1 regulates c-FLIP expression and protects cells from TNF-induced apoptosis and tissue injury.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/34693625","citation_count":16,"is_preprint":false},{"pmid":"35660018","id":"PMC_35660018","title":"TET2-BCLAF1 transcription repression complex epigenetically regulates the expression of colorectal cancer gene Ascl2 via methylation of its promoter.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35660018","citation_count":16,"is_preprint":false},{"pmid":"30661852","id":"PMC_30661852","title":"Structure-Guided Exploration of SDS22 Interactions with Protein Phosphatase PP1 and the Splicing Factor BCLAF1.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30661852","citation_count":16,"is_preprint":false},{"pmid":"34251713","id":"PMC_34251713","title":"Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34251713","citation_count":15,"is_preprint":false},{"pmid":"34088200","id":"PMC_34088200","title":"Evaluation of NOx removal from flue gas and Fe(II)EDTA regeneration using a novel BTF-ABR integrated system.","date":"2021","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/34088200","citation_count":13,"is_preprint":false},{"pmid":"38636894","id":"PMC_38636894","title":"BCLAF1 drives esophageal squamous cell carcinoma progression through regulation of YTHDF2-dependent SIX1 mRNA degradation.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38636894","citation_count":12,"is_preprint":false},{"pmid":"40442441","id":"PMC_40442441","title":"Targeting the BCKDK/BCLAF1/MYC/HK2 axis to alter aerobic glycolysis and overcome Trametinib resistance in lung cancer.","date":"2025","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/40442441","citation_count":8,"is_preprint":false},{"pmid":"35930920","id":"PMC_35930920","title":"BCLAF1, a functional partner of BACH1, participates in DNA damage response.","date":"2022","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/35930920","citation_count":7,"is_preprint":false},{"pmid":"11790742","id":"PMC_11790742","title":"Isolation and characterization of BTF-37: chromosomal DNA captured from Bacteroides fragilis that confers self-transferability and expresses a pilus-like structure in Bacteroides spp. and Escherichia coli.","date":"2002","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/11790742","citation_count":7,"is_preprint":false},{"pmid":"37906282","id":"PMC_37906282","title":"BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex.","date":"2023","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/37906282","citation_count":6,"is_preprint":false},{"pmid":"28895891","id":"PMC_28895891","title":"Alignment of Mitotic Chromosomes in Human Cells Involves SR-Like Splicing Factors Btf and TRAP150.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28895891","citation_count":6,"is_preprint":false},{"pmid":"38467765","id":"PMC_38467765","title":"Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK/eIF2α pathway.","date":"2024","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38467765","citation_count":6,"is_preprint":false},{"pmid":"39891142","id":"PMC_39891142","title":"Ionizing radiation-induced disruption of Rela-Bclaf1-spliceosome regulatory axis in primary spermatocytes causing spermatogenesis dysfunction.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39891142","citation_count":4,"is_preprint":false},{"pmid":"17720457","id":"PMC_17720457","title":"Characterization of BctA, a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37.","date":"2007","source":"Research in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17720457","citation_count":4,"is_preprint":false},{"pmid":"40220379","id":"PMC_40220379","title":"Bclaf1 mediates super-enhancer-driven activation of POLR2A to enhance chromatin accessibility in nitrosamine-induced esophageal carcinogenesis.","date":"2025","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/40220379","citation_count":3,"is_preprint":false},{"pmid":"35865489","id":"PMC_35865489","title":"Identifying and characterising Thrap3, Bclaf1 and Erh interactions using cross-linking mass spectrometry.","date":"2023","source":"Wellcome open research","url":"https://pubmed.ncbi.nlm.nih.gov/35865489","citation_count":3,"is_preprint":false},{"pmid":"40435510","id":"PMC_40435510","title":"BCLAF1 restrains stress responses in hematopoietic stem cells to support expansion and repopulation.","date":"2025","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/40435510","citation_count":3,"is_preprint":false},{"pmid":"38198022","id":"PMC_38198022","title":"BCLAF1 is Expressed as a Potential Anti-oncogene in Bile Duct Cancer.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38198022","citation_count":3,"is_preprint":false},{"pmid":"34512018","id":"PMC_34512018","title":"Role of Bclaf1 in Promoting Adrenocortical Carcinoma Proliferation: A Study Combining the Use of Bioinformatics and Molecular Events.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/34512018","citation_count":3,"is_preprint":false},{"pmid":"39990659","id":"PMC_39990659","title":"BCLAF1 Regulates Osteoarthritic Cartilage Degradation Through Interaction with LAMTOR2.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39990659","citation_count":2,"is_preprint":false},{"pmid":"38573525","id":"PMC_38573525","title":"Pan-Cancer Analysis Identifies BCLAF1 as a Potential Biomarker for Renal Cell Carcinoma.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38573525","citation_count":2,"is_preprint":false},{"pmid":"39444606","id":"PMC_39444606","title":"Sorbaria sorbifolia flavonoid derivative induces mitochondrial apoptosis in human hepatoma cells through Bclaf1.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39444606","citation_count":2,"is_preprint":false},{"pmid":"34490482","id":"PMC_34490482","title":"New insights from Whole Genome Sequencing: BCLAF1 deletion as a structural variant that predisposes cells towards cellular transformation.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34490482","citation_count":2,"is_preprint":false},{"pmid":"39366174","id":"PMC_39366174","title":"MED23 depletion induces premature senescence in NSCLC cells by interacting with BCLAF1 and then suppressing NUPR1 expression.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39366174","citation_count":1,"is_preprint":false},{"pmid":"23243848","id":"PMC_23243848","title":"[Characteristics of biofilm phase during the long-term degradation of a toluene-contaminated gas stream using BTF].","date":"2012","source":"Huan jing ke xue= Huanjing kexue","url":"https://pubmed.ncbi.nlm.nih.gov/23243848","citation_count":1,"is_preprint":false},{"pmid":"40016211","id":"PMC_40016211","title":"p85β acts as a transcription cofactor and cooperates with BCLAF1 in the nucleus.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40016211","citation_count":0,"is_preprint":false},{"pmid":"40635045","id":"PMC_40635045","title":"A novel MIR100HG transcript enhances tumorigenesis by inducing BCLAF1-mediated alternative splicing in colorectal cancer.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/40635045","citation_count":0,"is_preprint":false},{"pmid":"41648520","id":"PMC_41648520","title":"BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41648520","citation_count":0,"is_preprint":false},{"pmid":"36775032","id":"PMC_36775032","title":"Effects of various COD/NO ratios on NOx removal performance and microbial communities in a BTF-ABR integrated system.","date":"2023","source":"Chemosphere","url":"https://pubmed.ncbi.nlm.nih.gov/36775032","citation_count":0,"is_preprint":false},{"pmid":"41872140","id":"PMC_41872140","title":"Dynamic epigenetic regulation of BCLAF1 splicing in acute myeloid leukemia.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41872140","citation_count":0,"is_preprint":false},{"pmid":"42248374","id":"PMC_42248374","title":"Huangqi Jianzhong decoction inhibits CRC invasion through the modulation of BCLAF1-mediated glycolysis.","date":"2026","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42248374","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.04.636487","title":"Bclaf1 biomolecular condensates protect nuclear PTK2 from ubiquitin-proteasome system promoting cardiomyocyte survival during oxidative stress","date":"2025-02-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.04.636487","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.16.649147","title":"A microRNA CRISPR screen reveals miR-483-3p as an apoptotic regulator in prostate cancer","date":"2025-04-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.16.649147","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.11.669643","title":"Structure and function of a fungal AB toxin-like chimerolectin involved in anti-nematode defense","date":"2025-08-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.11.669643","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.07.606975","title":"Research on the Mechanism of Lphn1 Knockout in Inhibiting Colorectal Cancer","date":"2024-08-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.07.606975","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.20.24315403","title":"Improved Sensitivity For Detection Of Clinical Deterioration When Diagnostic Pathology And Patient Trends Are Included In Machine Learning Models","date":"2024-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.20.24315403","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.29.620871","title":"Single-Cell Atlas of AML Reveals Age-Related Gene Regulatory Networks in t(8;21) AML","date":"2024-11-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.29.620871","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":36796,"output_tokens":9873,"usd":0.129242,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20287,"output_tokens":7347,"usd":0.142555,"stage2_stop_reason":"end_turn"},"total_usd":0.271797,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"BCLAF1 (Btf) was identified as a novel protein that interacts with anti-apoptotic proteins E1B 19K, Bcl-2, and Bcl-xL but not with pro-apoptotic Bax. Btf binds DNA in vitro and represses transcription in reporter assays. E1B 19K, Bcl-2, and Bcl-xL sequester Btf in the cytoplasm and block its transcriptional repression activity. Sustained overexpression of Btf in HeLa cells induced apoptosis, which was inhibited by E1B 19K.\",\n      \"method\": \"Yeast two-hybrid screen, DNA binding assay in vitro, transcriptional reporter assay, subcellular localization, overexpression/apoptosis assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (yeast two-hybrid, in vitro DNA binding, reporter assay, cell-based apoptosis), foundational paper replicated in subsequent studies\",\n      \"pmids\": [\"10330179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Emerin binds BCLAF1 (Btf) with an equilibrium affinity (KD) of ~100 nM; this interaction was mapped to two regions of emerin flanking its lamin-binding domain. Disease-causing emerin mutation S54F selectively disrupts emerin binding to Btf without affecting binding to BAF, lamin A, or GCL. In non-apoptotic HeLa cells, endogenous Btf localizes to dot-like structures in the nuclear interior; upon Fas-induced apoptosis, Btf redistributes to a zone near the nuclear envelope, indicating apoptosis-regulated subcellular localization.\",\n      \"method\": \"Yeast two-hybrid, biochemical binding assay (equilibrium affinity), clustered alanine-substitution mutagenesis, indirect immunofluorescence\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — equilibrium binding assay with mutagenesis plus direct localization by immunofluorescence, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"15009215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PKCδ transactivates TP53 expression by interacting with BCLAF1 (Btf) and co-occupying the TP53 core promoter element (CPE-TP53). Inhibition of PKCδ activity decreases Btf affinity for CPE-TP53, reducing TP53 mRNA and protein levels. RNAi-mediated disruption of Btf-mediated TP53 transcription suppresses TP53-dependent apoptosis following genotoxic stress.\",\n      \"method\": \"Reporter assay (promoter activity), co-immunoprecipitation, ChIP (co-occupancy of CPE-TP53), RNAi knockdown with apoptosis readout\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ChIP, and reporter assay with RNAi functional validation in one study\",\n      \"pmids\": [\"17938203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Bclaf1 knockout mice demonstrate that Bclaf1 is required for proper spatial and temporal organization of smooth muscle lineage during the saccular stage of lung development and is essential for peripheral T-cell homeostasis. Bclaf1-deficient cells showed no defect in apoptosis in response to various apoptotic stimuli, contradicting its postulated role as a proapoptotic protein in vivo.\",\n      \"method\": \"Targeted gene knockout in mice, histological and cellular analysis of lung development and T-cell compartment\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout mouse with defined developmental and immune phenotypes, multiple tissue/cell-type readouts\",\n      \"pmids\": [\"19008920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sirt1 suppresses Bclaf1 transcription by deacetylating histone H3K56 at the bclaf1 promoter, counteracting p300-mediated H3K56 acetylation. Sirt1 is recruited to the bclaf1 promoter upon TCR/CD28 stimulation through a complex with p300 and NF-κB subunit Rel-A; blocking Rel-A nuclear translocation inhibits Sirt1 binding. Knockdown of Bclaf1 suppresses hyperactivation of Sirt1-null T cells.\",\n      \"method\": \"ChIP assay, siRNA knockdown, co-immunoprecipitation, histone acetylation analysis, T cell activation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, Co-IP, and functional knockdown with multiple orthogonal methods in one study\",\n      \"pmids\": [\"21454709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCLAF1 shows enhanced association with γH2AX specifically under high-dose ionizing radiation. BCLAF1 promotes apoptosis of irreparably damaged cells by disrupting p21-mediated inhibition of Caspase/cyclin E-dependent mitochondrial pathways. BCLAF1 co-localizes with γH2AX foci and stabilizes the Ku70/DNA-PKcs complex, facilitating NHEJ-based DSB repair in surviving cells. In tumor cells, BCLAF1 is intrinsically suppressed, leading to formation of anti-apoptotic Ku70-Bax complexes and disrupted Ku70/DNA-PKcs complexes.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, NHEJ repair assay, apoptosis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and co-localization with functional readouts, single lab\",\n      \"pmids\": [\"22833098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCLAF1 functions as a restriction factor against human cytomegalovirus (HCMV). Immediately after infection, viral pp71 and UL35 proteins (delivered via virions) direct proteasomal degradation of BCLAF1. At late infection stages, virus-encoded miR-UL112-1 down-regulates BCLAF1. In the absence of BCLAF1 neutralization, viral gene expression and replication are inhibited.\",\n      \"method\": \"Protein degradation assay, viral miRNA functional assay, viral gene expression/replication assay with BCLAF1 knockdown/rescue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two mechanistically distinct viral neutralization pathways experimentally identified with functional consequences on viral replication\",\n      \"pmids\": [\"22645331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BCLAF1 (Btf) localizes at active transcription loci in a RNA Pol II-dependent manner and shows overlap with the exon junction complex protein Magoh. Btf depletion causes increased β-tropomyosin reporter transcripts and global increase of endogenous polyadenylated RNA in the cytoplasm, indicating a role for Btf in restricting mRNA nuclear export; TRAP150 depletion did not produce this effect.\",\n      \"method\": \"Fluorescence microscopy (localization at reporter gene loci), siRNA knockdown, nuclear/cytoplasmic fractionation with RT-PCR\",\n      \"journal\": \"Nucleus (Austin, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence (mRNA distribution) using knockdown and fractionation, single lab\",\n      \"pmids\": [\"23778535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The splicing factor SRSF10 stimulates inclusion of BCLAF1 alternative exon5a, producing a specific BCLAF1 protein isoform. Knockdown of this exon5a-containing isoform inhibited growth of colorectal cancer cells, while its overexpression increased tumorigenic potential.\",\n      \"method\": \"Splicing assay, siRNA knockdown, overexpression, cell growth and tumorigenicity assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic splicing regulation identified with functional consequences, multiple cell-based methods, published in high-impact journal\",\n      \"pmids\": [\"25091051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BCLAF1 is upregulated through the ATM/Nemo/NF-κB pathway during doxorubicin-induced senescence (TIS) and is a direct transcriptional target of p65 and c-Rel. BCLAF1 induction by NF-κB is required for C/EBPβ upregulation and IL-6/IL-8 transcription during TIS. BCLAF1 interacts with the leucine zipper region of C/EBPβ to cooperate in upregulating IL-8. BCLAF1 is required for effectiveness of doxorubicin-induced tumor suppression in a xenograft model.\",\n      \"method\": \"ChIP, co-immunoprecipitation, siRNA knockdown, reporter assay, xenograft tumor model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, Co-IP, and functional knockdown with multiple orthogonal methods in one study\",\n      \"pmids\": [\"26794446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCLAF1 and THRAP3 promote the DNA damage response by selective mRNA splicing and nuclear export of DDR transcripts, including ATM kinase mRNA. Loss of THRAP3 and/or BCLAF1 leads to sensitivity to DNA damaging agents, defective DNA repair, and genomic instability. Cancer-associated mutations in THRAP3 result in deregulated processing of THRAP3/BCLAF1-regulated transcripts and defective DNA repair.\",\n      \"method\": \"siRNA knockdown, DNA damage sensitivity assays, DNA repair assays, genomic instability assays, mRNA splicing/export analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with multiple orthogonal readouts (DNA repair, splicing, export), independently supported by clinical mutation data\",\n      \"pmids\": [\"29112714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Depletion of BCLAF1 (Btf) and/or TRAP150 causes mitotic chromosome misalignment defects and altered abundance of transcripts encoding mitotic regulators, suggesting that Btf controls transcript abundance of mitotic checkpoint regulators, thereby affecting mitotic progression.\",\n      \"method\": \"siRNA knockdown, immunofluorescence (mitotic defects), RT-PCR (transcript levels)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — knockdown with cellular phenotype and mRNA-level evidence, indirect mechanistic link, single lab\",\n      \"pmids\": [\"28895891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BCLAF1 promotes HIF1A transcription via its bZIP domain in hepatocellular carcinoma cells, leading to increased transcription of VEGFA, TGFB, and EPO, which promote HCC-associated angiogenesis. HIF-1α levels and microvessel density decrease after shRNA-mediated BCLAF1 knockdown in xenograft tumors. A positive feedback loop exists: HIF-1α induces BCLAF1, which in turn stabilizes HIF-1α expression.\",\n      \"method\": \"shRNA knockdown, reporter assay, domain deletion (bZIP), xenograft tumor model, qRT-PCR, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-based mechanistic evidence with in vivo xenograft validation, single lab\",\n      \"pmids\": [\"30367150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cry2 (but not Cry1) specifically interacts with BCLAF1 to stabilize mRNAs encoding cyclin D1 and Tmem176b, regulating circadian patterns of myoblast proliferation and myotube formation. BCLAF1 knockdown recapitulates Cry2 knockdown phenotypes: premature cell cycle exit and inefficient myogenic cell fusion.\",\n      \"method\": \"Co-immunoprecipitation, mRNA stability assay, siRNA knockdown, Cry2 knockout mice, myogenic differentiation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP establishing Cry2-BCLAF1 interaction, mRNA stability assay, genetic KO and KD with parallel phenotypes across multiple methods\",\n      \"pmids\": [\"29466738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BCLAF1 is degraded during alphaherpesvirus PRV and HSV-1 infection through the viral protein US3. BCLAF1 functions in type I interferon signaling by maintaining efficient STAT1 and STAT2 phosphorylation in response to IFNα and by directly interacting with ISRE sequences and STAT2 to facilitate ISGF3 binding for gene transcription. Knockdown or knockout of BCLAF1 significantly impairs IFNα-mediated gene transcription and antiviral activity.\",\n      \"method\": \"Protein degradation assay, Co-immunoprecipitation, ChIP/DNA binding assay, siRNA/CRISPR knockout, antiviral functional assays, STAT phosphorylation assay\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (IP, DNA binding, knockout, signaling assays) establishing mechanism of BCLAF1 in IFN signaling\",\n      \"pmids\": [\"30682178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of SDS22 reveals a large basic surface patch that enables binding of a phosphorylated form of splicing factor BCLAF1. Biochemical studies show SDS22 acts as a 'third' subunit of multiple PP1 holoenzymes and recruits phospho-BCLAF1.\",\n      \"method\": \"X-ray crystallography (SDS22 structure), biochemical binding assays, modeling\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with biochemical validation; interaction is structural and biochemically confirmed, single lab\",\n      \"pmids\": [\"30661852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RAG DNA double-strand breaks in pre-B cells activate a SPIC/BCLAF1 transcription factor complex. SPIC recruits BCLAF1 to gene-regulatory elements controlling expression of key B cell developmental genes. The SPIC/BCLAF1 complex suppresses SYK tyrosine kinase expression and enforces the transition from large to small pre-B cells.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, gene expression analysis, B cell developmental assays in pre-B cell models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus ChIP-seq with functional developmental readout, multiple orthogonal methods\",\n      \"pmids\": [\"31644907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCLAF1 is a direct transcriptional target of HIF-1 and is upregulated during hypoxia. BCLAF1 binds HIF-1α in the nucleus, and this interaction is required for BCLAF1 to stabilize HIF-1α during long-term hypoxia. BCLAF1 knockout cells show greatly reduced HIF-1α protein stability and impaired induction of HIF-1 target gene transcription after prolonged hypoxia.\",\n      \"method\": \"ChIP (HIF-1 binding to BCLAF1 promoter), Co-immunoprecipitation (BCLAF1-HIF-1α), CRISPR knockout, HIF-1α stability assays, xenograft tumor model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, Co-IP, and CRISPR knockout with in vivo validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"32029898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BCLAF1 exerts anti-apoptotic function in TNF signaling by promoting transcription of CFLAR (encoding c-FLIP, a caspase 8 antagonist) downstream of NF-κB activation. BCLAF1 binds to the p50 subunit of NF-κB, which is required for BCLAF1 to stimulate CFLAR transcription. BCLAF1 depletion sensitizes cells to TNF-induced apoptosis but not necroptosis, and exacerbates TNF-induced small intestine injury in mice.\",\n      \"method\": \"Co-immunoprecipitation (BCLAF1-p50 interaction), siRNA knockdown, reporter assay, apoptosis/necroptosis assays, in vivo mouse model (siRNA administration)\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifying binding partner, reporter assay for mechanism, and in vivo validation with multiple orthogonal methods\",\n      \"pmids\": [\"34693625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"lncCIRBIL directly binds to BCLAF1 protein and inhibits its nuclear translocation. Cardiomyocyte-specific Bclaf1 overexpression worsens cardiac I/R injury, while partial Bclaf1 knockout mitigates it. Partial Bclaf1 knockout abrogates the detrimental effects of lncCIRBIL knockout, placing Bclaf1 downstream of lncCIRBIL in cardiac I/R injury.\",\n      \"method\": \"RNA-protein binding assay (lncCIRBIL-BCLAF1 interaction), nuclear translocation assay, transgenic overexpression and knockout mice, I/R injury model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated with localization and genetic epistasis in vivo; regulatory relationship is lncRNA-protein so some indirection, single lab\",\n      \"pmids\": [\"33483496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ATM activation in response to ionizing radiation leads to BCLAF1-dependent regulation of PD-L1 stability. BCLAF1 depletion decreases PD-L1 expression by promoting its ubiquitination. CMTM6 is upregulated in response to IR and participates in BCLAF1-dependent PD-L1 upregulation. The ATM/BCLAF1/PD-L1 axis was identified by mass spectrometry and validated by co-immunoprecipitation.\",\n      \"method\": \"Mass spectrometry (PD-L1 interactome), co-immunoprecipitation, ubiquitination assay, siRNA knockdown, T cell co-culture assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-identified interaction validated by Co-IP and ubiquitination assay, single lab\",\n      \"pmids\": [\"34251713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TET2 and BCLAF1 form a transcription repression complex in CRC cells. The TET2-BCLAF1 complex binds multiple elements around CCGG sites at the Ascl2 promoter and restrains its hypermethylation by inducing hydroxymethylation. BCLAF1 was identified as a TET2 interactor by LC-MS/MS and validated by co-immunoprecipitation, immunofluorescence co-localization, and proximity ligation assays.\",\n      \"method\": \"LC-MS/MS, co-immunoprecipitation, immunofluorescence co-localization, proximity ligation assay, ChIP-qPCR, glucosylated hydroxymethyl-qPCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — MS identification validated by four orthogonal interaction assays plus ChIP-qPCR for functional chromatin binding\",\n      \"pmids\": [\"35660018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCLAF1 physically interacts with SPOP (an E3 ubiquitin ligase) via an SPOP-binding consensus (SBC) motif on BCLAF1, competitively inhibiting SPOP-PD-L1 interaction and subsequent ubiquitination and degradation of PD-L1. Mutation of the BCLAF1-SBC motif disrupts regulation of the SPOP-PD-L1 axis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis of SBC motif, T cell co-culture model, in vitro competition assay\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP with mutagenesis validation and functional ubiquitination assay with T cell readout\",\n      \"pmids\": [\"38340178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCLAF1 silencing in smooth muscle cells (SMCs) led to downregulation of BCL2 and SMC markers, reduced proliferation, and increased apoptosis. oxLDL-induced transdifferentiation of SMCs was accompanied by BCLAF1 upregulation, and BCLAF1 silencing during oxLDL exposure preserved MYH11 expression and prevented SMC transdifferentiation. BCLAF1 was shown to interact with BCL2 by proximity ligation assay in plaque cells.\",\n      \"method\": \"siRNA knockdown, proximity ligation assay (BCLAF1-BCL2 interaction), oxLDL treatment, immunohistochemistry, lineage-tracing mouse model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity ligation for interaction plus functional knockdown; in vivo lineage tracing adds context, single lab\",\n      \"pmids\": [\"35321563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCLAF1 was identified as a binding partner of BACH1 by tandem protein affinity purification. BCLAF1 constitutively interacts with BACH1 regardless of DNA damage, but in response to DNA damage, BCLAF1 is recruited to DNA damage sites in a BACH1- and BRCA1-dependent manner. BCLAF1-deficient cells are defective for DSB-initiated homologous recombination, but RAD51 foci formation is intact.\",\n      \"method\": \"Tandem protein affinity purification, co-immunoprecipitation, recruitment to DNA damage sites (foci assay), HR repair assay, RAD51 foci assay\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity purification and Co-IP with mechanistic HR assay, single lab\",\n      \"pmids\": [\"35930920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cross-linking mass spectrometry (XL-MS) of endogenous protein complexes identified crosslinks between BCLAF1, THRAP3, and ERH, mapping interaction surfaces to non-disordered portions of both BCLAF1 and THRAP3, suggesting these three proteins form a novel complex (TEB complex).\",\n      \"method\": \"Cross-linking mass spectrometry (XL-MS with DSSO crosslinker) after immunoprecipitation of endogenous complexes\",\n      \"journal\": \"Wellcome open research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structural interaction mapping via XL-MS of endogenous proteins, single lab, no functional validation of complex\",\n      \"pmids\": [\"35865489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCLAF1 promotes HIF-1α accumulation under normoxia by interacting with CUL3 (Cullin 3) ubiquitin ligase, promoting ubiquitination and degradation of PHD2 (prolyl hydroxylase domain protein 2), thereby stabilizing HIF-1α. This leads to HIF-1α-dependent PD-L1 transcription. BCLAF1-CUL3 interaction validated by co-immunoprecipitation and immunofluorescence.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, PHD2 ubiquitination assay, Western blot, RT-qPCR\",\n      \"journal\": \"Cancer immunology, immunotherapy : CII\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ubiquitination assay, single lab, mechanistic cascade supported by multiple assays\",\n      \"pmids\": [\"37906282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCLAF1 interacts with YTHDF2 (an m6A reader) in ESCC cells, reducing YTHDF2's tumor-suppressive activities. BCLAF1-YTHDF2 interaction was validated by mass spectrometry, co-localization, co-immunoprecipitation, and GST pull-down. This interaction leads to stabilization of SIX1 mRNA (normally degraded by YTHDF2), promoting glycolysis and cancer progression in an m6A-specific manner.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation, GST pull-down, MeRIP-seq, RIP-seq, transcriptomic analysis\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — interaction identified by MS and validated by three orthogonal methods (Co-IP, GST pull-down, co-localization) plus mechanism established by MeRIP-seq and RIP-seq\",\n      \"pmids\": [\"38636894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCLAF1 interacts with LAMTOR2, and LAMTOR2 regulates the nuclear translocation of BCLAF1 in chondrocytes. BCLAF1 knockdown inhibits catabolic factor expression and apoptosis in chondrocytes while promoting anabolic factors, and intra-articular injection of Bclaf1 shRNA attenuates OA cartilage degradation in mice.\",\n      \"method\": \"Immunoprecipitation, protein mass spectrometry, nuclear translocation assay, siRNA/shRNA knockdown, overexpression, in vivo mouse OA model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IP-MS identification of LAMTOR2 with nuclear translocation assay and in vivo functional validation, single lab\",\n      \"pmids\": [\"39990659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MED23 physically interacts with BCLAF1 in NSCLC cells, as identified by co-IP and mass spectrometry (validated by PLA assays). The MED23/BCLAF1 complex regulates transcription of NUPR1, which controls autophagic flux; loss of MED23 reduces NUPR1 expression and triggers premature senescence.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, proximity ligation assay, RNA-seq, ChIP assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-identified interaction validated by PLA and ChIP-confirmed target gene regulation, single lab\",\n      \"pmids\": [\"39366174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCKDK phosphorylates BCLAF1 at serine 285, facilitating BCLAF1 binding to the MYC promoter and enhancing MYC transcription in lung cancer cells. Elevated MYC then upregulates hexokinase 2 (HK2), promoting aerobic glycolysis and Trametinib resistance. BCKDK-BCLAF1 interaction was identified through molecular biology experiments.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assay (S285 site), ChIP (BCLAF1 at MYC promoter), site-directed mutagenesis, functional glycolysis assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus phosphorylation site identification and ChIP supporting mechanistic model, single lab\",\n      \"pmids\": [\"40442441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Nuclear p85β physically interacts with BCLAF1 and shows genome-wide co-occupancy at gene targets. BCLAF1 recruits p85β to BCLAF1 gene loci, and p85β facilitates assembly of a complex containing BCLAF1, TRIM28, and ZNF263, which together activate BCLAF1 transcription (positive autoregulation). Multi-omics analysis confirmed physical interaction and functional cooperativity.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq (co-occupancy), RNA-seq, multi-omics approach\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP validated by ChIP-seq co-occupancy with multi-omics functional cooperativity, multiple orthogonal methods\",\n      \"pmids\": [\"40016211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCLAF1 physically associates with core spliceosome components and regulates alternative splicing with a predominant effect on intron retention. BCLAF1 is required for productive splicing of ATF4 mRNA to sustain ATF4 protein expression and downstream metabolic gene regulation. Loss of BCLAF1 reduces ATF4 protein levels, disrupts de novo amino acid biosynthesis, and sensitizes AML cells to venetoclax.\",\n      \"method\": \"Co-immunoprecipitation (spliceosome components), RNA-seq/alternative splicing analysis, ATF4 protein/mRNA assays, metabolomics, venetoclax sensitivity assay\",\n      \"journal\": \"bioRxiv : the preprint server for biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with spliceosome, splicing analysis, and mechanistic downstream validation; preprint, single lab\",\n      \"pmids\": [\"41648520\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bclaf1 undergoes liquid-liquid phase separation (LLPS) to form nuclear biomolecular condensates during oxidative stress in cardiomyocytes. PTK2 sequestered within Bclaf1 condensates is protected from ubiquitin-proteasome-mediated degradation at lysine 926. Disruption of Bclaf1 condensates leads to PTK2 degradation, increased p53 levels, and increased apoptosis.\",\n      \"method\": \"Advanced microscopy (LLPS/condensate visualization), ubiquitination assay, proteasome inhibition, site-directed mutagenesis (K926), Bclaf1 knockdown with apoptosis readout\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — LLPS and ubiquitination site identified with functional consequence; preprint, single lab, novel finding needing peer review\",\n      \"pmids\": [\"bio_10.1101_2025.02.04.636487\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCLAF1 promotes chromatin accessibility in esophageal carcinoma by activating POLR2A (RNA polymerase II subunit) through two mechanisms: (1) transcriptional activation via co-recruitment of BCLAF1/P300/H3K27ac at the POLR2A super-enhancer (E2/E3 elements), and (2) splicing regulation of pre-POLR2A mRNA through interaction with SNRPA (small nuclear ribonucleoprotein polypeptide A).\",\n      \"method\": \"ATAC-seq (chromatin accessibility), CUT&Tag (co-occupancy at POLR2A super-enhancer), RNA-binding protein immunoprecipitation (RIP) for SNRPA interaction, siRNA knockdown, in vitro and in vivo models\",\n      \"journal\": \"Journal of hazardous materials\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CUT&Tag and RIP establish dual mechanism with ATAC-seq phenotype, single lab\",\n      \"pmids\": [\"40220379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCLAF1 restrains stress response gene expression in hematopoietic stem cells (HSCs) and promotes HSC repopulation activity. BCLAF1 associates with chromatin throughout the genome of fetal and adult hematopoietic cells to regulate transcriptional programs. Loss of BCLAF1 impairs HSC self-renewal and multilineage reconstitution after stem cell transplantation.\",\n      \"method\": \"Hematopoietic-specific and inducible deletion (Cre-lox), single-cell RNA-seq, chromatin association assay, stem cell transplantation/reconstitution assay\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with scRNA-seq and chromatin association data plus functional transplantation assay, multiple orthogonal methods\",\n      \"pmids\": [\"40435510\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCLAF1 is a multifunctional nuclear protein that (1) represses transcription by binding DNA via its bZIP and Myb-like domains, with anti-apoptotic Bcl-2 family members sequestering it in the cytoplasm to block this activity; (2) regulates alternative splicing and mRNA nuclear export as an SR-like splicing factor that associates with spliceosome components and the exon junction complex; (3) participates in the DNA damage response by interacting with γH2AX, stabilizing the Ku70/DNA-PKcs NHEJ complex, and acting as a functional partner of BACH1 for homologous recombination; (4) transduces NF-κB signaling to C/EBPβ during senescence and promotes c-FLIP transcription downstream of NF-κB to protect against TNF-induced apoptosis; (5) stabilizes HIF-1α protein in the nucleus under hypoxia, driving a positive HIF-1/BCLAF1 feedback loop and promoting angiogenesis; (6) interacts with SPOP and CUL3 to regulate PD-L1 stability via the ubiquitin-proteasome system; (7) forms condensates that protect binding partners (e.g., PTK2) from proteasomal degradation; and (8) is itself regulated post-translationally by PKCδ-mediated activation, BCKDK-mediated phosphorylation at S285, SDS22-recruited PP1 (via phospho-BCLAF1), and by viral factors (HCMV pp71/UL35 proteasomal degradation, HSV-1/PRV US3 degradation) that neutralize its antiviral restriction activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCLAF1 is a multifunctional nuclear protein that integrates transcriptional regulation, RNA processing, and stress signaling to control cell fate decisions across development, immunity, and tumorigenesis [#0, #3, #35]. It was originally identified as a DNA-binding transcriptional repressor sequestered in the cytoplasm by anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL, E1B 19K), with sustained overexpression driving apoptosis [#0]. As a chromatin-associated factor it occupies target promoters in partnership with diverse transcription factors and cofactors: it co-occupies the TP53 promoter with PKCδ to drive p53-dependent apoptosis [#2], cooperates with C/EBPβ and NF-κB subunits (p65/c-Rel during senescence, p50 to induce the caspase-8 antagonist c-FLIP) [#9, #18], partners with SPIC to enforce pre-B cell development [#16], forms a repressive complex with TET2 to control DNA methylation at target loci [#21], and positively autoregulates its own transcription via a complex with p85β, TRIM28, and ZNF263 [#31]. In parallel, BCLAF1 functions as an SR-like splicing and mRNA-export factor that associates with the exon junction complex and core spliceosome and, together with THRAP3, controls splicing and nuclear export of DNA-damage-response transcripts including ATM mRNA, thereby safeguarding genome stability [#7, #10, #32]. It additionally participates directly in DNA repair by associating with γH2AX, stabilizing the Ku70/DNA-PKcs NHEJ complex, and acting as a BACH1- and BRCA1-dependent partner in homologous recombination [#5, #24]. BCLAF1 is a transcriptional target and stabilizer of HIF-1α under hypoxia, forming a positive feedback loop that drives angiogenesis and, via CUL3-dependent PHD2 degradation, sustains HIF-1α and PD-L1 even under normoxia [#12, #17, #26]. Its activity is tuned post-translationally by PKCδ, BCKDK-mediated phosphorylation at Ser285 (promoting MYC transcription and glycolysis), and phospho-dependent recruitment of PP1 via SDS22, and its nuclear translocation is gated by LAMTOR2 and lncCIRBIL [#2, #30, #15, #28, #19]. BCLAF1 acts as a restriction factor against cytomegalovirus and alphaherpesviruses and supports type I interferon signaling by maintaining STAT phosphorylation and ISGF3 promoter binding; viral proteins (HCMV pp71/UL35, HSV-1/PRV US3) neutralize it by proteasomal degradation [#6, #14]. In vivo, BCLAF1 is required for lung smooth muscle organization, peripheral T-cell homeostasis, and hematopoietic stem cell self-renewal, with knockout cells showing no intrinsic apoptosis defect, refining its originally postulated proapoptotic role [#3, #35].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established BCLAF1's founding identity as a DNA-binding transcriptional repressor whose activity is held in check by anti-apoptotic Bcl-2 proteins, linking it to apoptotic control.\",\n      \"evidence\": \"Yeast two-hybrid screen, in vitro DNA binding, reporter assay, and overexpression apoptosis assay in HeLa cells\",\n      \"pmids\": [\"10330179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct DNA target sequences and endogenous repressed genes not defined\", \"Whether apoptosis is a physiological function untested in vivo at this stage\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapped a high-affinity emerin interaction and showed apoptosis-regulated relocalization, tying BCLAF1 to the nuclear envelope and a disease-relevant mutation.\",\n      \"evidence\": \"Equilibrium binding assay, alanine-scanning mutagenesis, and immunofluorescence in HeLa cells\",\n      \"pmids\": [\"15009215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of emerin binding for BCLAF1 activity not established\", \"Significance of nuclear-interior dot localization unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined a concrete transcriptional target and upstream kinase by showing PKCδ interacts with BCLAF1 to co-occupy and activate the TP53 promoter, enabling genotoxic stress apoptosis.\",\n      \"evidence\": \"Co-IP, ChIP co-occupancy at CPE-TP53, reporter assay, and RNAi with apoptosis readout\",\n      \"pmids\": [\"17938203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKCδ directly phosphorylates BCLAF1 not shown\", \"Broader PKCδ-dependent target gene set undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed BCLAF1's essential developmental and immune roles in vivo and overturned the assumption that it is intrinsically proapoptotic.\",\n      \"evidence\": \"Targeted knockout mice with lung developmental and T-cell compartment analysis\",\n      \"pmids\": [\"19008920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism behind lung and T-cell phenotypes not defined\", \"Reconciliation with cell-line proapoptotic data left open\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Placed BCLAF1 under NF-κB/Sirt1-controlled epigenetic regulation, showing its expression is dynamically gated during T-cell activation.\",\n      \"evidence\": \"ChIP, Co-IP, histone H3K56 acetylation analysis, and siRNA in T cells\",\n      \"pmids\": [\"21454709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BCLAF1 effector genes in activated T cells not identified\", \"Whether BCLAF1 feeds back on NF-κB unaddressed at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected BCLAF1 to the DNA damage response and to viral restriction, establishing dual roles in NHEJ-based repair and innate antiviral defense.\",\n      \"evidence\": \"Co-IP, γH2AX co-localization and NHEJ assays; viral degradation and replication assays for HCMV\",\n      \"pmids\": [\"22833098\", \"22645331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which BCLAF1 stabilizes Ku70/DNA-PKcs not structurally defined\", \"How tumor cells suppress BCLAF1 unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined BCLAF1 as an RNA-processing factor at active transcription loci that restricts mRNA nuclear export, distinguishing it functionally from its paralog TRAP150.\",\n      \"evidence\": \"Reporter-locus microscopy, EJC (Magoh) overlap, siRNA, and nuclear/cytoplasmic fractionation with RT-PCR\",\n      \"pmids\": [\"23778535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RNA substrates not catalogued\", \"Molecular basis of export restriction unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed BCLAF1 is itself a splicing-regulated gene whose SRSF10-driven exon5a isoform has oncogenic activity, linking its isoform identity to tumor phenotypes.\",\n      \"evidence\": \"Splicing assay, siRNA, overexpression, and tumorigenicity assays in colorectal cancer cells\",\n      \"pmids\": [\"25091051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional difference between isoforms at the protein level not defined\", \"Whether isoform switching alters partner binding unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined BCLAF1 as an NF-κB-induced transducer to C/EBPβ during therapy-induced senescence, controlling SASP cytokine output and tumor suppression.\",\n      \"evidence\": \"ChIP, Co-IP with C/EBPβ leucine zipper, reporter assay, siRNA, and xenograft model\",\n      \"pmids\": [\"26794446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCLAF1 acts as transcription factor or cofactor at IL-6/IL-8 loci not fully resolved\", \"Generality across senescence triggers untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established a unifying mechanism whereby BCLAF1/THRAP3 control DDR via selective splicing and export of repair transcripts, and linked BCLAF1 to mitotic transcript control.\",\n      \"evidence\": \"siRNA, DNA damage sensitivity and repair assays, splicing/export analysis, and mitotic phenotype/RT-PCR readouts\",\n      \"pmids\": [\"29112714\", \"28895891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RNA-binding specificity determinants not defined\", \"Direct versus indirect effects on mitotic regulators unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified a HIF-1α/BCLAF1 positive feedback loop and a Cry2-coupled mRNA-stabilizing function, expanding BCLAF1's roles into hypoxic angiogenesis and circadian myogenesis.\",\n      \"evidence\": \"shRNA, reporter and bZIP domain-deletion assays, xenograft for HIF1A; Co-IP, mRNA stability assays and Cry2 KO mice for circadian function\",\n      \"pmids\": [\"30367150\", \"29466738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BCLAF1 stabilizes HIF-1α mechanistically not yet defined at this stage\", \"Determinants of Cry2-selective mRNA targeting unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined BCLAF1 as a STAT/ISGF3-supporting interferon effector, a SPIC-recruited B-cell developmental regulator, and a phospho-dependent PP1 substrate, broadening its signaling and post-translational regulatory repertoire.\",\n      \"evidence\": \"Co-IP, ChIP/DNA binding, CRISPR KO and antiviral assays (IFN); Co-IP and ChIP-seq (SPIC); X-ray crystallography of SDS22 with phospho-BCLAF1 binding\",\n      \"pmids\": [\"30682178\", \"31644907\", \"30661852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosites recognized by SDS22/PP1 not mapped at this stage\", \"How US3 selects BCLAF1 for degradation unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved the HIF-1α stabilization mechanism by showing nuclear BCLAF1 binds HIF-1α directly and is required to sustain it during prolonged hypoxia.\",\n      \"evidence\": \"ChIP, Co-IP, CRISPR knockout, HIF-1α stability assays, and xenograft model\",\n      \"pmids\": [\"32029898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical basis of HIF-1α protection by BCLAF1 not fully defined\", \"Whether stabilization requires BCLAF1 chromatin function unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established BCLAF1 as an NF-κB-p50-dependent anti-apoptotic transcriptional driver of c-FLIP and as a lncRNA-gated mediator of cardiac injury, refining its context-dependent cell-death roles.\",\n      \"evidence\": \"Co-IP with p50, reporter assay, apoptosis/necroptosis assays and intestinal injury model (CFLAR); RNA-protein binding, nuclear translocation, and transgenic I/R models (lncCIRBIL)\",\n      \"pmids\": [\"34693625\", \"33483496\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same protein switches between pro- and anti-apoptotic outputs not unified\", \"lncCIRBIL binding site on BCLAF1 not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked ATM-activated BCLAF1 to PD-L1 stability, implicating BCLAF1 in immune evasion downstream of DNA damage.\",\n      \"evidence\": \"Mass spectrometry, Co-IP, ubiquitination assay, siRNA, and T-cell co-culture\",\n      \"pmids\": [\"34251713\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism by which BCLAF1 protects PD-L1 from ubiquitination unclear\", \"Single-lab MS-based interaction\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded BCLAF1's interactome and PD-L1 regulation, revealing TET2 repressive complex formation, BACH1/BRCA1-dependent HR, competitive SPOP inhibition stabilizing PD-L1, and a BCL2-linked smooth-muscle role.\",\n      \"evidence\": \"LC-MS/MS, Co-IP, PLA and ChIP (TET2); affinity purification and HR assays (BACH1); SBC-motif mutagenesis and ubiquitination assays (SPOP); siRNA, PLA and lineage tracing (BCL2/SMC)\",\n      \"pmids\": [\"35660018\", \"35930920\", \"38340178\", \"35321563\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BCLAF1 partitions among these complexes within a cell unknown\", \"Stoichiometry and mutual exclusivity of partners undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Structurally placed BCLAF1 in a defined TEB complex with THRAP3 and ERH and resolved an alternate normoxic HIF-1α stabilization route via CUL3-dependent PHD2 degradation.\",\n      \"evidence\": \"Cross-linking mass spectrometry of endogenous complexes (TEB); Co-IP, immunofluorescence and PHD2 ubiquitination assays (CUL3)\",\n      \"pmids\": [\"35865489\", \"37906282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of the TEB complex not tested\", \"Whether CUL3-PHD2 and direct HIF-1α binding mechanisms coexist or compete unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected BCLAF1 to m6A-RNA metabolism via YTHDF2 antagonism and to lysosomal/mTOR-adjacent signaling via LAMTOR2-gated nuclear translocation, expanding its post-transcriptional and localization control.\",\n      \"evidence\": \"MS, Co-IP, GST pull-down, MeRIP/RIP-seq (YTHDF2); IP-MS, nuclear translocation, knockdown and OA model (LAMTOR2)\",\n      \"pmids\": [\"38636894\", \"39990659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCLAF1 alters YTHDF2 catalytic engagement or sequesters it not distinguished\", \"How LAMTOR2 controls BCLAF1 import mechanistically unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined upstream phospho-control by BCKDK at Ser285 and a cofactor partnership with MED23, linking BCLAF1 to MYC-driven glycolysis, drug resistance, and autophagy/senescence transcriptional programs.\",\n      \"evidence\": \"Co-IP, S285 phosphorylation assay, ChIP and glycolysis assays (BCKDK/MYC); Co-IP, PLA, RNA-seq and ChIP (MED23/NUPR1)\",\n      \"pmids\": [\"40442441\", \"39366174\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How Ser285 phosphorylation alters BCLAF1 DNA binding biochemically unresolved\", \"Single-lab studies awaiting independent confirmation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established BCLAF1's autoregulatory transcription circuit, its requirement for HSC self-renewal, and a dual transcription/splicing mechanism controlling POLR2A and chromatin accessibility.\",\n      \"evidence\": \"Co-IP and ChIP-seq with p85β/TRIM28/ZNF263 (autoregulation); conditional KO, scRNA-seq and transplantation (HSC); ATAC-seq, CUT&Tag and RIP with SNRPA (POLR2A)\",\n      \"pmids\": [\"40016211\", \"40435510\", \"40220379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How autoregulation is set or reset across cell states unknown\", \"Whether the POLR2A dual mechanism generalizes beyond esophageal carcinoma untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Proposed condensate-based and splicing-based protective mechanisms, with BCLAF1 phase separation shielding PTK2 from degradation and BCLAF1-dependent ATF4 splicing sustaining amino-acid metabolism.\",\n      \"evidence\": \"LLPS imaging, ubiquitination and K926 mutagenesis assays (PTK2, preprint); Co-IP with spliceosome, splicing analysis, metabolomics and venetoclax sensitivity (ATF4, preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.02.04.636487\", \"41648520\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Both findings are preprints awaiting peer review\", \"Determinants of BCLAF1 condensate formation and client selection not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single protein coordinates its DNA-binding/transcription, splicing/export, DNA-repair, and condensate functions, and what determines its partitioning among the many mutually exclusive partner complexes and post-translational states.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of full-length BCLAF1 or its domain-specific partner engagement\", \"Rules governing context-dependent pro- versus anti-apoptotic outputs unknown\", \"Whether splicing, transcription, and condensate roles are temporally or spatially separated undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 14]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 9, 16, 21, 31]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [7, 10, 13, 27, 32]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [10, 32, 34]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [12, 17, 22, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 7, 17, 35]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [7, 31, 33]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [16, 21, 31, 34, 35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 9, 16, 21, 31]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [7, 10, 13, 27, 32]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [5, 10, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 14, 16, 35]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [9, 12, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 5, 18]}\n    ],\n    \"complexes\": [\"TEB complex (BCLAF1-THRAP3-ERH)\", \"SPIC/BCLAF1 transcription complex\", \"TET2-BCLAF1 repression complex\", \"Ku70/DNA-PKcs NHEJ complex\"],\n    \"partners\": [\"THRAP3\", \"HIF1A\", \"BACH1\", \"TET2\", \"SPOP\", \"CUL3\", \"C/EBPβ\", \"YTHDF2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}